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Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall
synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a
last resort antibiotic. However, since the emergence of the first vancomycin-resistant
enterococci in 1987, vancomycin resistance has become widespread, especially in
hospitals. We have synthesized and evaluated 110 vancomycin analogs modified at the
C-terminal carboxyl group of the heptapeptide moiety with R2NHR1NH2 substituents.
Through iterative optimizations of the substituents, we identified vancomycin analogs
that fully restore (or even exceed) the original inhibitory activity against vancomycin-
resistant enterococci (VRE), vancomycin-intermediate (VISA) and vancomycin-resistant
Staphylococcus aureus (VRSA) strains. The best analogs have improved growth
inhibitory activity and in vitro therapeutic indices against a broad set of VRE and
methicillin-resistant S. aureus (MRSA) isolates. They also exceed the activity of
vancomycin against Clostridium difficile ribotypes. Vanc-39 and Vanc-42 have a
low probability to provoke antibiotic resistance, and overcome different vancomycin
resistance mechanisms (VanA, VanB, and VanC1).
Keywords: vancomycin analog, VRE, MRSA, resistance, chemical engineering, in vitro therapeutic index
INTRODUCTION
Vancomycin is a glycopeptide antibiotic that is widely used for the treatment of life-
threatening infections caused by Gram-positive methicillin-resistant Staphylococcus aureus
(MRSA), enterococci and Clostridium difficile, and which are unresponsive to other antibiotics.
Vancomycin is also the antibiotic-of-choice for patients who are allergic to β-lactam
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antibiotics (Ingerman and Santoro, 1989). Vancomycin exerts its
antibacterial effect through inhibition of cell wall crosslinking
by binding to the terminal D-Ala-D-Ala residues of membrane-
anchored lipid II (Walsh, 1999). Despite the fact that vancomycin
was kept as a drug of last resort, enterococci have developed
extensive resistance (vancomycin-resistant enterococci or VRE).
Altered lipid II with terminal D-Ala-D-Lac is the most
prevalent resistance mechanism of VRE (VanA and VanB
type), leading to the loss of one hydrogen bond and a
consequent 1000-fold reduced affinity for vancomycin (Arthur
and Courvalin, 1993; Walsh et al., 1996). Indeed, interaction
of vancomycin to the terminal D-Ala-D-Ala is mediated
through hydrogen bonds with the heptapeptide backbone. In
addition, N-methylleucine, which is the first amino acid of
the heptapeptide backbone, does not take part in hydrogen
bonding but is essential for an intact binding pocket as shown
by molecular dynamics simulations (Wang et al., 2018). Other
resistance mechanisms imply the formation of D-Ala-D-Ser
termini (VanC, VanE, and VanG) (Reynolds et al., 1994; McKessar
et al., 2000; Abadía Patiño et al., 2002). Vancomycin is also
frequently used for the treatment of MRSA infections, and
vancomycin-resistant strains have been reported. Vancomycin-
intermediate S. aureus (VISA) strains have a thickened and
poorly crosslinked cell wall with abundant D-Ala-D-Ala sites
sequestering vancomycin (Cui et al., 2003). Vancomycin-
resistant S. aureus (VRSA) strains have a similar resistance
mechanism as VRE due to horizontal transfer of the vanA
operon.
In response to the emergence of vancomycin-resistant strains,
second-generation lipoglycopeptides have been designed to
combat vancomycin-resistant strains. Vancomycin has been
chemically modified in a semisynthetic approach either at
the N- or C-terminus of the heptapeptide backbone, or at
the vancosamine group in the carbohydrate moiety. These
are non-binding site modifications, and thus generally do
not affect the binding affinity with the terminal residues
of lipid II. Accordingly, alternative mode of actions have
been attributed to different groups of vancomycin analogs.
Dimerization of some vancomycin analogs is achieved through
hydrophobic substitutions (e.g., lipidation) at the vancosamine
group and appears to result in cooperative binding of the
lipid II termini (Allen et al., 1996). These substitutions also
increase membrane anchoring, which may conceivably result
in a better binding of the vancomycin analog to the lipid II
termini. Other vancomycin analogs are suggested to show
improved bactericidal activity by membrane depolarization, e.g.,
through coupling a lipophilic cationic quaternary ammonium
moiety to the C-terminus of vancomycin (Yarlagadda et al.,
2014). Chlorobiphenyl (CBP) substituents on the disaccharide
result in analogs that do not bind D-Ala-D-Lac but directly
inhibit transglycosylase activity through enzyme binding
(Chen et al., 2003). In spite of the efficacy of modifications
with lipophilic substituents, the latter may also result in long
elimination half-lifes and accumulative toxicity. Recently, Guan
et al. (2018) reported that the introduction of hydrophilic
substituents like sugar moieties counteracts the negative effects
of lipophilic substituents, resulting in an enhanced efficacy,
optimal pharmacokinetics and a lower toxicity. Modifications
in the core structure of vancomycin, which comprises the
binding site of vancomycin to D-Ala-D-Ala, have remained
largely unexplored, as this requires total synthesis of the
vancomycin analogs. This is particularly challenging given
the structural complexity of vancomycin. However, Crowley
and Boger (2006) succeeded in reengineering the binding
pocket for balanced, dual binding characteristics to both
D-Ala-D-Ala and D-Ala-D-Lac using total synthesis. Parallel
to this study, the same group recently presented several
vancomycin analogs with synergistically acting modifications at
the heptapeptide backbone, the C-terminus (cationic quaternary
ammonium salt), and the vancomycin disaccharide (CBP
substituent), resulting in more durable antibiotics with less
propensity to acquire resistance against the three mechanisms
of actions (Okano et al., 2017a). A complete review on the
total syntheses of vancomycin-related glycopeptide antibiotics
including their modifications and key analogs has been
published by the Boger group (Okano et al., 2017b). Oritavancin
(a chlorophenylbenzyl derivative of chloroeremomycin, a
vancomycin-like glycopeptide), televancin (derived from
vancomycin with substituents on the vancosamine group and
the peptide core) and dalbavancin (a semi-synthetic derivative
of the natural teicoplanin-like lipoglycopeptide A-40926)
are three FDA-approved semisynthetic second-generation
glycolpeptides.
Another approach is the synthesis of bifunctional hybrids
such as vancomycin-nisin conjugates. These conjugates were
found to show improved antibacterial activity against VRE
compared to the unconjugated molecules (Arnusch et al.,
2008). We previously reported the synthesis of conjugates
of vancomycin and cathelicidin-related antimicrobial peptide
(CRAMP) using click chemistry with diverse hydrophilic and
hydrophobic linkers. Our hypothesis was that CRAMP could
act as a carrier molecule for the transfer of the vancomycin
moiety through the outer membrane of Gram-negative bacteria,
conferring antibacterial activity against both Gram-positive and
Gram-negative bacteria to the conjugates. Small hydrophobic
linkers with an aromatic group eventually resulted in the most
active conjugates against planktonic Gram-negative bacteria,
while maintaining the high activity of vancomycin against
Gram-positive bacteria (Mishra et al., 2015). In an attempt
to understand these findings, we synthesized vancomycin
analogs substituted with the linker molecules corresponding to
our previous study, but without the CRAMP moiety. These
analogs lost their activity against Gram-negative species, but
serendipitously, we found that the vancomycin analogs with
the hydrophobic substituents showed a strongly increased
inhibitory activity against VRE. These initial analogs with
hydrophobic substituents proved, however, highly toxic for cell
lines in vitro, presumably due to the increased hydrophobicity.
We therefore initiated a program to synthesize novel vancomycin
analogs in iterative rounds to gradually find an optimal
balance between hydrophobicity and hydrophilicity of the
substituent, and identified analogs with superior antibacterial
activity against VRE, MRSA and C. difficile without in vitro
cytotoxicity.
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MATERIALS AND METHODS
Synthesis of Vancomycin Analogs
All vancomycin analogs were designed and synthesized
by amide coupling. The substituents (R2NHR1) were
synthesized in two or more synthetic steps with good
yield. These R2NHR1NH2 moieties were attached to the
C-terminus of the heptapeptide backbone of the vancomycin.
For the amidation of the glycopeptide, coupling reagents
EDC·HCl and HOAt were used to provide the target amide
as predominant product. All vancomycin derivatives were
purified by preparative HPLC. Full details on the synthesis
have been added as Supplementary Information. In total, seven
different synthesis rounds of new vancomycin analogs were
performed.
Bacterial Strains, Growth Conditions and
Antibiotics
Vancomycin-sensitive and vancomycin-resistant Enterococcus
faecalis strains and methicillin-resistant S. aureus (MRSA)
strains included clinical isolates collected at the university
hospital UZ Leuven (Belgium). The vancomycin-sensitive
S. aureus strain was ATCC 6538 (Rosenbach). The vancomycine-
intermediate S. aureus (VISA) HIP5827 (Tenover et al., 1998)
and vancomycin-resistant S. aureus (VRSA) were kindly donated
by Olivier Denis (Université Libre de Bruxelles, Belgium).
E. faecalis and S. aureus strains were grown at 37◦C on
brain heart infusion (BHI; Becton-Dickinson, Erembodegem,
Belgium) agar and lysogeny broth (LB; also known as Luria-
Bertani medium) agar plates, respectively. C. difficile strain
ATJ ribotype 014/20 and strain AIU ribotype 027 were kept
on brain heart infusion agar plates, grown at 37◦C in an
anaerobic cabinet. Vancomycin, daptomycin, tigeglycine, and
linezolid were purchased from Selleck Chemicals (Munich,
Germany).
Minimum Inhibitory Concentration and
Minimum Bactericidal Concentration
Against E. faecalis and S. aureus
The minimum inhibitory concentration (MIC) was determined
using the broth microdilution method according to the
antimicrobial susceptibility testing standards of the clinical and
laboratory standards institute (Clinical and Laboratory Standards
Institute [CLSI], 2012). Ultrapure water and non-inoculated
broth were used as controls. In one case, a final concentration
of 10 µM vancomycin was included with the vancomycin analog
or control antibiotic. The MIC was determined after 24 h at
37◦C as the minimum concentration that fully inhibited cell
growth.
To monitor resistance development upon exposure to
subinhibitory doses, the initial MIC of Vanc-39, Vanc-42 and
daptomycin was determined against VRE 39. A new MIC assay
was prepared using 1,000-fold diluted cells grown at MIC/2
(occasionally MIC/4 if growth in MIC/2 was too limited).
This was repeated for 20 cycles and changes in MIC were
monitored.
To determine the minimal bactericidal concentration (MBC),
the same MIC experiment as described above was set up,
and the content of wells showing no growth after 24 h was
completely plated on BHI and LB agar plates for VRE and
MRSA, respectively. Plates were incubated overnight at 37◦C and
colony growth was inspected. The compound concentration that
corresponded to the well which did not contain viable bacteria is
the minimum bactericidal concentration.
Minimum Inhibitory Concentration
Against C. difficile
Bacterial lawns of both C. difficile strains were prepared
by adding 0.5 mL overnight culture to 8 mL sloppy BHI
agar (0.4% agar) supplemented with 1.5 g/L CaCl2·2H2O and
81.2 g/L MgCl2·6H2O, and pouring the mixture into Petri plates.
A twofold dilution series of the selected vancomycin analogs,
vancomycin (0.012 µM) and daptomycin (25 µM) was spotted
(10 µL) on the bacterial lawn. Spots were air-dried and the
plates were incubated overnight at 37◦C in an anaerobic cabinet.
Ultrapure water was included as negative control. The assay
was performed in triplicate. Inhibition was observed by cleared
spots.
Cytostatic Activity Against Mammalian
Cell Lines
Murine leukemia (L1210), human T-lymphocyte (CEM) and the
human cervix carcinoma (HeLa) cell line were suspended at
300,000–500,000 cells/mL of culture medium, and 100 µL of a
cell suspension was added to 100 µL of an appropriate dilution
of the test compounds in wells of 96-well microtiter plates. After
incubation at 37◦C for 2 (L1210), 3 (CEM), or 4 (HeLa) days,
the cell number was determined using a Coulter counter. The
IC50 was defined per cell type as the compound concentration
required to inhibit cell proliferation by 50% compared to the
negative control (Glowacka et al., 2017).
Time-Kill Curves
Time-kill curves were determined based on the CLSI guidelines
(Clinical and Laboratory Standards Institute [CLSI], 1999).
Single colonies grown overnight at 37◦C were resuspended in
Ca2+-adjusted (0.05 mg/mL) Mueller Hinton broth up to an
optical density (625 nm) of 0.08–00.10 (corresponding to the
0.5 McFarland standard), followed by a 10-fold dilution in the
same broth. Subsequently, 0.2 mL inoculum was added to 1.7 mL
Ca2+-adjusted (0.05 mg/mL) Mueller Hinton broth, followed
by addition of the antibacterial compound (0.1 mL). The final
concentration of the antibacterial compound corresponded to the
4x MIC value for that compound. For the antibiotic-free control,
the compound was replaced by an equal volume of ultrapure
water. The final inoculum concentration was approximately 106
CFU/mL. The cultures were continuously shaken at 37◦C. After 1,
2, 4, 6, 8, and 24 h, a 0.1 mL aliquot was removed, serially diluted
in cold 0.9% w/v NaCl and plated on BHI (VRE) and LB (MRSA)
agar plates. Plates were incubated overnight at 37◦C and colonies
were counted.
Frontiers in Microbiology | www.frontiersin.org 3 June 2018 | Volume 9 | Article 1175
fmicb-09-01175 June 7, 2018 Time: 14:53 # 4
Mishra et al. Chemical Engineering of Vancomycin Analogs
FIGURE 1 | General structure of vancomycin analogs. The C-terminal carboxyl group of the peptide within the vancomycin structure is substituted with
R2NHR1NH-groups.
RESULTS
Vancomycin Analogs Substituted With
Hydrophobic Groups Are Active
Against VRE
Eighteen vancomycin analogs substituted with hydrophilic and
hydrophobic groups, corresponding to the linkers between
vancomycin and CRAMP used in our previous study (Mishra
et al., 2015), were synthesized and purified (Figure 1 and
Supplementary Information). The minimum inhibitory
concentration (MIC) was determined against a Bacillus
subtilis, an Escherichia coli, a vancomycin-sensitive E. faecalis
and two vancomycin-resistant strains (VRE6 and VRE53;
both VanA type). The former two were selected as model
organisms for a Gram-positive and Gram-negative bacterium,
respectively, similar to our previous study. Enterococci were
included to analyze the effects of substitution on vancomycin
resistance. The data are expressed in µM to allow for direct
comparison given the molecular weight differences between
the analogs. The vancomycin analogs show a slightly decreased
MIC against B. subtilis (0.5- to 2-fold MIC decreases) or E. coli
(1- to 8-fold decreases) compared to vancomycin, but six
substituents resulted in analogs with also a strongly decreased
MIC against vancomycin-sensitive E. faecalis (2- to 64-fold)
and vancomycin-resistant E. faecalis strains (4- to 256-fold)
(Supplementary Table S1). These substituents are (unlike the
other substituents used) all hydrophobic. Specifically, five of six
vancomycin analogs (Vanc-N, Vanc-Q, Vanc-R, Vanc-S, and
Vanc-T) share a (poly)aromatic substituent (aniline-glycine and
benzoic acid/cinnamic/naphthoic acid derivatives) whereas the
sixth, weaker compound (Vanc-B) has an aliphatic substituent
(Supplementary Information).
Iterative Rounds of Vancomycin Analog
Synthesis Lead to Improved Compounds
Because hydrophobic substituents may result in undesired
cytotoxic effects, the concentration that inhibits the growth
in vitro of three cell lines (L1210, CEM, HeLa) by 50% (IC50)
was determined. Whereas vancomycin, Vanc-B, Vanc-N, and
Vanc-Q do not show toxicity (IC50 > 250 µM), Vanc-R,
Vanc-S, and Vanc-T have low average IC50 values between
1.4 ± 0.6 and 15 ± 1, 5.6 ± 1.1 and 70 ± 8, and 60 ± 10
and 77 ± 17, respectively, depending on the cell line used
(Supplementary Table S2). When correlating the MIC values of
these six vancomycin analogs against VRE to their IC50 values,
a generally positive correlation between inhibitory effect and
toxicity is observed, with the strongest inhibitory compounds
also being relatively more toxic, as illustrated for VRE29
(Figure 2A). In subsequent series of chemical synthesis of novel
vancomycin analogs (Supplementary Information), we aimed to
design molecules that have a strong inhibitory effect, but lack
or have a reduced toxic effect on mammalian cells. In total,
ninety-two additional vancomycin analogs were synthesized,
purified and characterized. All analogs were evaluated for their
inhibitory effect (MIC) against a set of one vancomycin-sensitive
E. faecalis and four vancomycin-resistant strains (all VanA type),
and for their in vitro cytotoxic effect against the above mentioned
three cell lines. Three antibiotics (tigecycline, daptomycin,
and linezolid) which are currently used (off-label) against
VRE infections, and vancomycin were included as controls
(Supplementary Tables S2, S3). Vancomycin analogs showing
a better profile (i.e., higher inhibitory effects and lower or no
cytotoxicity) were identified. These superior analogs (e.g., Vanc-
42 and Vanc-83, Table 1) show a fully restored inhibitory activity
with similar MIC values for VRE strains as vancomycin for a
vancomycin-sensitive strain (VSE; 1.56 µM), while IC50 values
increased. Vanc-39 shows no cytotoxicity (IC50 > 250 µM), while
displaying a good inhibitory effect (Figure 2A).
We investigated the susceptibility of a methicillin-susceptible
S. aureus (MSSA) strain, four MRSA strains, one VISA and one
VRSA strain for all vancomycin analogs and control antibiotics
(Supplementary Table S4). The large majority of vancomycin
analogs showed an improved inhibitory effect against MSSA
(up to 16-fold) and MRSA (up to 8-fold), but mainly against
VISA (up to 128-fold), and VRSA (up to 512-fold). The best
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FIGURE 2 | Relationship between inhibitory activity and mammalian cytotoxicity. The relationship between the IC50 value and MIC-fold change compared to
vancomycin is shown for all vancomycin analogs and control antibiotics against VRE (A) and MRSA (B). The IC50 value is the average value of the IC50 against the
L1210, CEM and HeLa cell lines; if it is > 250 µM, then it is plotted as if it were equal to 250 µM. Symbols: first series of analogs (Vanc-B-Vanc-T) (#), other series of
vancomycin analogs (1), tigeclycine (), linezolid ( ), daptomycin () and vancomycin (N) are shown. Vancomycin analogs selected for further characterization are
highlighted.
vancomycin analogs against VRSA show a MIC value that is up
to fourfold lower than the MIC value of unmodified vancomycin
against the tested VSSA. This shows that the resistance is fully
reverted. These observations for both VRSA and VRE show
that the analogs either have an improved binding to D-Ala-
D-Lac termini, or that the analogs have a secondary mode of
action. The generally increased susceptibility of vancomycin-
susceptible strains such as VSSA, MRSA and VSE support the
latter hypothesis. In addition, the substituents are added at the
C-terminus, which is a non-binding site for vancomycin.
Since VRSA strains are relatively rare, the correlation between
the IC50 and MIC values was analyzed for the more prevalent
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MRSA strains instead. Figure 2B shows that Vanc-39, Vanc-42,
and Vanc-83 which display a good profile against VRE strains,
also perform well for MRSA. In contrast Vanc-81 performs well
in case of MRSA but only shows a moderate improvement
against VRE. Vanc-39, Vanc-42, and Vanc-83 were therefore
selected for further analysis, together with Vanc-24 and Vanc-
66, which have a more moderate profile, but differ significantly
from the other selected compounds in terms of the chemical
nature of the substituent (Table 1). Vanc-24 possesses an
indole ring and Vanc-66 has 4-isopropyl-N-(naphthalen-2-
yl)benzenesulfonamide moiety as R2 and a propyl chain as
R1, whereas in Vanc-39, Vanc-42 and Vanc-83 R1 is an acetyl
group. Vanc-39, Vanc-42 and Vanc-83 possess a butyl benzene,
a fluorene moiety and a biphenyl ring as R2 substituent,
respectively.
The Best Analogs Have Improved in Vitro
Therapeutic Indices Compared to
Current Antibiotics
Vanc-24, Vanc-39, Vanc-42, Vanc-66, and Vanc-83 were tested
against a broad set of 33 VRE isolates and 24 MRSA isolates, along
with the control antibiotics linezolid, tigecycline, daptomycin
and vancomycin. The MIC50 value was determined as the
median value for each set and used for the calculation of an
in vitro estimator of the therapeutic index (TI = IC50/MIC50)
as a reference for the window between the in vitro effective
inhibitory and mammalian cytotoxic dose (Supplementary Table
S5). Comparison of the in vitro therapeutic indices for VRE
(Figure 3A) shows similar or improved values compared to
TABLE 1 | Substituents of selected vancomycin analogs.
Vancomycin analogs R2NHR1NH-
Vanc-24
Vanc-39
Vanc-42
Vanc-66
Vanc-83
The specific structures of substituents (R2NHR1NH-) of selected vancomycin
analogs characterized in detail in this study are given.
current alternatives, with Vanc-42 (111) showing the best index,
exceeding those of linezolid, tigecycline and daptomycine. Due to
resistance, the MIC50 value of vancomycin is higher than its IC50
value, resulting in a TI < 1. In the case of MRSA, the in vitro
TI values are much higher, peaking at 865 for Vanc-42, which
is approximately 100 times higher than linezolid and tigecycline
tested under the same conditions. Also other vancomycin analogs
score well above an in vitro therapeutic index of 200 (Figure 3B).
A Selection of Vancomycin Analogs
Shows Improved Activity Against
C. difficile Compared to Vancomycin
Oral vancomycin is the treatment of choice for severe C. difficile
colitis in patients who cannot tolerate the first-choice antibiotic
metronidazole (Shen and Surawicz, 2008). Therefore, we
investigated a subset of vancomycin analogs against the two most
prevalent C. difficile ribotypes (014/20 and 027). All vancomycin
analogs showed an improved inhibitory effect against both
ribotypes, but to a different extent. The increased inhibitory effect
is largest for Vanc-42, Vanc-48, and Vanc-66 with up to 45-
and 58-fold reduced MIC values for ribotype 014/20 and 027,
respectively (Supplementary Table S6).
Vancomycin Analogs Are Bactericidal
Against MRSA but Bacteriostatic Against
VRE
Besides the inhibitory concentrations, also the minimum
bactericidal concentrations (MBCs) were determined against
VRE and MRSA. In the case of the latter, Vanc-24, Vanc-39,
Vanc-42, Vanc-66, Vanc-83, vancomycin and daptomycin have a
MBC equaling their MIC values, showing the bactericidal action
of these antibacterials against MRSA. Linezolid and tigecycline
have an MBC that is more than four times higher than the
corresponding MIC. For VRE, the MBC values were at least
four times higher than the MIC values for all antibiotics. All
compounds thus display a lower bactericidal activity against VRE
compared to MRSA.
To quantify the bactericidal effects of the five selected
vancomycin analogs against MRSA, time-kill curves were
determined (Figure 4). Stationary phase cells (106 CFU/ml) were
exposed to an antibiotic concentration corresponding to 4x MIC
and the surviving number of cells was quantified after 1, 2, 4, 6, 8,
and 24 h. All vancomycin analogs cause a relatively similar time-
dependent bactericidal effect with a 4–5 log reduction after 24 h,
with Vanc-24 showing the quickest onset of killing. The time-kill
curves of the analogs are similar to that of vancomycin, which
acts slower than daptomycin that causes a complete elimination
after 24 h. Linezolid and tigecycline show a typical bacteriostatic
time-kill curve.
Vanc-39 and Vanc-42 Have a Low
Probability to Provoke Antibiotic
Resistance by Genetic Alterations
The risk to develop resistance by genetic mutations against two
selected vancomycin analogs (Vanc-39, Vanc-42) was evaluated
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FIGURE 3 | Comparison of in vitro therapeutic indices. The in vitro therapeutic indices, calculated as the ratio of IC50 and MIC50 (i.e., the median MIC value for the
respective set of isolates) are compared for five selected vancomycin analogs and four control antibiotics against 33 clinical VRE (A) and 24 clinical MRSA (B)
isolates.
through serial exposure of VRE to subinhibitory doses (=MIC/2).
Daptomycin was included as control antibiotic. The MIC was
determined after each cycle. For daptomycin, the MIC increased
stepwise in cycle 2, 4, and 14 to an eightfold higher concentration,
which is best explained by the putative gain of specific mutations
[e.g., in the cardiolipin synthase (Palmer et al., 2011)]. The MIC
values for Vanc-39 and Vanc-42 oscillated between the original
value and a twofold increase, which falls within the typical
variation of MIC determinations (Figure 5). These observations
indicate that Vanc-39 and Vanc-42 have a lower probability
to elicit resistance development by genetic mutations (vertical
transfer) compared to daptomycin.
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FIGURE 4 | Time-kill curves. Semi-log plot of time-kill curves (n = 3, mean ± standard deviation) of MRSA exposed to a dose corresponding to 4x MIC of
(A) Vanc-24 (), Vanc-39 (#), Vanc-42 (x), Vanc-66 (1), and Vanc-83 (♦); (B) daptomycin (x), vancomycin (1), linezolid (), tigecycline (#), and ultrapure water (♦)
are shown.
The Vancomycin Analogs Overcome
Different Vancomycin Resistance
Mechanisms
All VRE strains analyzed for susceptibility so far have the VanA
genotype with D-Ala-D-Lac termini. Therefore, five VanB- and
one VanC1-type vancomycin-resistant Enterococcus strains were
evaluated (Supplementary Table S7). VanB-type strains have also
the D-Ala-D-Lac dipeptide, but differ in the regulation of the
operon that leads to the production of altered peptidoglycan
precursors. These strains are sensitive to teicoplanin unlike
VanA-type strains. The VanC-type resistance mechanism is due
to the presence of a D-Ala-D-Ser dipeptide, which has less affinity
for vancomycin because of steric hindrance. The vanC1 operon is
found in Enterococcus gallinarum. All strains showed a similar
susceptibility, albeit at the lower end of the range (Vanc-39,
Vanc-42, and Vanc-83) or just below (Vanc-24 and Vanc-66) the
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FIGURE 5 | Resistance development. Changes in the MIC against Vanc-39 (♦), Vanc-42 () and daptomycin (#) were monitored over 20 cycles of serial exposure
to subinhibitory doses.
range observed for VanA-type strains (Supplementary Table S5).
The VanC1-type strain was generally slightly more susceptible
than VanB-type strains, especially for Vanc-24.
We evaluated the hypothesis that vancomycin analogs may
have restored activity against VRE strains due to the lack of
recognition of these analogs by membrane-bound VanS. This
component of the VanR-VanS two-component regulator senses
the presence of vancomycin and activates transcription of the
vanA operon leading to the hydrolysis of D-Ala-D-Ala precursors
and the synthesis of D-Ala-D-Lac precursors. If the vancomycin
analogs are no longer recognized, peptidoglycan precursors will
not be altered, explaining why these strains remain susceptible.
Therefore, the MIC of VRE37 was analyzed in the presence
of 10 µM vancomycin, which is significantly above the MIC
of a vancomycin-sensitive strain and is expected to induce the
vanA gene cluster with subsequent production of D-Ala-D-
Lac peptidoglycan precursors. However, no significant increases
in MIC were observed (Supplementary Table S8), refuting
this hypothesis. In addition, the VanC1-type strain, which
constitutively expresses vancomycin resistance independent of
recognition, is also susceptible to the different vancomycin
analogs tested (Supplementary Table S7), confirming these
findings.
DISCUSSION
The golden era of antibiotic discovery yielded a multitude
of antibiotic classes by screening antibacterial activity of
actinomycetes, via the so-called Waksman platform. Since then,
many semi-synthetic derivatives of these natural antibiotics
have entered the clinic. For instance, the latest variants of
quinolones and cephalosporines belong to the fourth generation.
Vancomycin was discovered in 1953, but remarkably few semi-
synthetic derivatives have entered the market. Those that did
were only recently approved, such as televancin for complicated
skin and skin structure infections (2009), and hospital-acquired
and ventilator-associated bacterial pneumonia (2013) caused by
S. aureus; dalbavancin and oritavancin were recently approved
for the treatment of acute bacterial skin and skin structure
infections (2014). This may be explained best by (1) the
complex structure of vancomycin, which was only correctly
determined in 1982 almost 30 years after its discovery (Harris
et al., 1983), (2) the limited number of functional groups
available for modification, (3) the initial difficulties associated
with total organic synthesis, which were only eliminated in the
late 1990s when three independent groups successfully achieved
total synthesis of vancomycin (Okano et al., 2017b) and (4)
the late emergence of vancomycin resistance. Starting from our
efforts to synthesize vancomycin-CRAMP hybrids that show
activity against Gram-negative bacteria (Mishra et al., 2015), we
serendipitously discovered vancomycin analogs that were not
affected by vancomycin resistance mechanisms in enterococci.
An initial series of vancomycin analogs with substituents showing
large chemical diversity highlighted the potential of hydrophobic
substituents to avoid vancomycin resistance mechanisms. These
findings are consistent with the increased inhibitory activity
of other vancomycin analogs with hydrophobic substituents,
albeit with a different structure, a different attachment site and
different covalent linkage (Chen et al., 2003; Mu et al., 2004;
Olsuf ’eva and Preobrazhenskaya, 2006; Pinchman and Boger,
2013; Printsevskaya et al., 2013; Yarlagadda et al., 2014). Iterative
rounds of synthesis of novel substituents yielded vancomycin
analogs with high inhibitory activity and lower or no in vitro
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toxicity for mammalian cell lines. The best analogs (e.g., Vanc-83)
completely restore in vitro susceptibility of VRE strains to the
level of susceptibility of VSE for vancomycin. Others show no
in vitro mammalian cytotoxicity, while preserving an increased
inhibitory activity against VRE (e.g., Vanc-39). We used an
in vitro estimator of the therapeutic index to select the most
promising analogs with the broadest window between the
minimum inhibitory dose and mammalian cytotoxic dose. Vanc-
42 was identified as the best analog on a broad set of clinical
VRE isolates, and shows in vitro a better therapeutic index than
drugs currently used for VRE treatment. Moreover, Vanc-42
shows inhibitory activity against both VanA-, VanB-, and VanC-
type strains, and a low probability for resistance development by
vertical transfer was demonstrated. Vanc-42 was also confirmed
as a promising candidate with the best in vitro therapeutic
index against a broad set of MRSA isolates. In addition,
Vanc-42 is among the best in vitro inhibitors of relevant strains
of the two most prevalent C. difficile ribotypes. Noteworthy,
the best vancomycin analogs show an improved balance in
hydrophobicity and hydrophilicity, with the hydrophobic moiety
likely contributing to an increased efficacy against vancomycin-
resistance strains, while the hydrophilic moiety appears to
compensate for the observed toxicity, eventually leading to
analogs with improved therapeutic indices. These findings are in
agreement with a recent study by Guan et al. (2018), reporting on
the development of new vancomycin analogs. They introduced
extra hydrophilic sugar moieties to eliminate the toxicity induced
by the lipophilic substitutions.
CONCLUSION
Our study shows that the amide-based coupling of R2NHR1
substituents to vancomycin is convenient as it requires only
two synthetic steps. The method can be efficiently used in
an iterative approach to generate libraries of analogs with an
improved in vitro therapeutic index against VRE, MRSA, and
C. difficile as potential next generation vancomycin analogs for
therapeutic use.
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